Assessment of patients with spondyloarthropathies for treatment with tumour necrosis factor α blockade

Rheumatology

Volumn 44, Issue 1, 2005, Pages 17-23

  Paul, S ^a,b   Keat, Andrew ^a  

^a NORTHWICK PARK HOSPITAL   (United Kingdom)

^b ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; CORTICOSTEROID DERIVATIVE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; LYMPHOTOXIN; METHOTREXATE; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; TUMOR NECROSIS FACTOR ALPHA CONVERTING ENZYME INHIBITOR; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ANKYLOSING SPONDYLITIS; CLINICAL FEATURE; CLINICAL PRACTICE; CLINICAL TRIAL; DRUG EFFICACY; DRUG HALF LIFE; DRUG RECEPTOR BINDING; ENTEROPATHY; FATIGUE; HEALTH CARE ORGANIZATION; HUMAN; JOINT STIFFNESS; MEDICAL ASSESSMENT; MEDICAL SOCIETY; PRESCRIPTION; PRIORITY JOURNAL; PSORIATIC ARTHRITIS; QUALITY OF LIFE; REACTIVE ARTHRITIS; REMISSION; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; SPINAL PAIN; SPONDYLOARTHROPATHY; SYMPTOMATOLOGY; TREATMENT OUTCOME; TREATMENT PLANNING; UNITED KINGDOM; UVEITIS;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; BIOLOGICAL RESPONSE MODIFIERS; HUMANS; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; SPONDYLARTHROPATHIES; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 12344254072     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/keh358     Document Type: Review

References (59)

1. Beutler BA. The role of tumor necrosis factor in health and disease. J Rheumatol 1999;26(Suppl. 57):16-21.
2. Maini RN, St Clair EW, Breedveld FC et al. Infliximab (chimeric anti-tumor necrosis factor monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised Phase III trial. Lancet 1999;354:1932-9.
3. Hanauer SB, Fagan BG, Lichenstein GR et al. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 2002;359:1541-8.
4. Chaudhari U, Romano P, Mulcahy LD, Dooley LT, Baker DG, Gottlieb AB. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-7.
5. Braun J, Bollow M, Neure L et al. Use of immunohistologic and in situ hybridisation techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 1995;38:499-505.
6. Braun J, Khan MA, Sieper J. Enthesitis and ankylosis in spondyloarthropathy: what is the target immune response? Ann Rheum Dis 2000;59:985-94.
7. Canete JD, Llena J, Collado A et al. Comparative cytokine gene expression in synovial tissue of early rheumatoid arthritis and seronegative spondyloarthropathies. Br J Rheumatol 1997;36:38-42.
8. Gratacos J, Collado A, Fillella X et al. Serum cytokines (IL-6, TNFα, IL-1B and IFNγ) in ankylosing spondylitis: a close correlation between IL-6 and disease activity and severity. Br J Rheumatol 1994;33:927-31.
9. Ribbens C, Andre B, Kaye O et al. Increased synovial fluid levels of interleukin-12, sCD25 and sTNF-RII/sTNF-RI ratio delineate a cytokine pattern characteristic of immune arthropathies. Eur Cytokine Netw 2000;11:669-76.
10. Braun J, Yin Z, Spiller I, Siegert S et al. Low secretion of tumor necrosis factor alpha, but no other Th1 or Th2 cytokines, by peripheral blood mononuclear cells correlates with chronicity in reactive arthritis. Arthritis Rheum 1999;42:2039-44.
11. Victor FC, Gottlieb AB. TNF-γ and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol 2002;1:264-75.
12. Ritchlin CT, Haas-Smith SA, Li P, Hicks DG, Schwarz EM. Mechanisms of TNF-α- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. J Clin Invest 2003; 111:821-31.
13. Sandborn WJ, Hanauer SB. Anti tumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results and safety. Inflamm Bowel Dis 1999;5:119-33.
14. Santos Lacomba M, Marcos Martin C, Gallardo Galera JM et al. Aqueous humor and serum tumor necrosis factor-α in clinical uveitis. Ophthalmic Res 2001;33:251-5.
15. Spoorenberg A, van der Heijde D, de Klerk E et al. Relative value of erythrocyte sedimentation rate and C-reactive protein in assessment of disease activity in ankylosing spondylitis. J Rheumatol 1999; 26:980-4.
16. van der Heijde D, Braun J, McGonagle D, Siegel J. Treatment trials in ankylosing spondylitis: current and future considerations. Ann Rheum Dis 2002;61(Suppl. 111):iii24-iii32.
17. Garrett S, Jenkinson T, Gail Kennedy L, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
18. Calin A, Garrett SL, Whitelock HC, Gail Kennedy L et al. A new approach to defining functional ability in ankylosing spondylitis. The development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol 1994;21:2281-5.
19. Dougados M, Gueguen A, Nakache J, Nguyen M, Mery C, Amor B. Evaluation of a functional index and an articular index in ankylosing spondylitis. J Rheumatol 1988;15:302-7.
20. Jenkinson TR, Mallorie PA, Whitelock HC, Gail Kennedy L, Garrett SL, Calin A. A Defining spinal mobility in ankylosing spondylitis (AS). The Bath AS Metrology Index. J Rheumatol 1994; 21:1694-8.
21. Anderson JJ, Baron G, van der Heijde D, Felson DT, Felson M. ASAS preliminary criteria for short term improvement in ankylosing spondylitis. Arthritis Rheum 2001;44:1876-86.
22. Stone M, Salonen D, Lax M, Payne U, Inman R. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. J Rheumatol 2001;28:1605-14.
23. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondyloarthropathy. Arthritis Rheum 2001;44:2112-7.
24. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D for the ASAS working group. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003; 62:817-24.
25. Fredriksson T, Petterson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
26. Brandt J, Haibel H, Cornely D et al. Successful treatment of active ankylosing spondylitis with the anti-tumour necrosis factor α monoclonal antibody infliximab. Arthritis Rheum 2000;43:1346-52.
27. van den Bosch F, Kruithof E, Baeten D, De Keyser F, Mielants H, Veys EM. Effects of a loading dose regimen of three infusions of chimeric antibody to tumour necrosis factor α (infliximab) in spondyloarthropathy: an open pilot study. Ann Rheum Dis 2000;59: 428-33.
28. Braun J, Brandt J, Listing J, Zink A et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 2002;359:1187-93.
29. van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984;27:361-8.
30. Braun J, Brandt J, Listing J et al. Long term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomised, placebo-controlled trial. Arthritis Rheum 2002;48:2224-33.
31. Van den Bosch F, Kruithof E, Baeten D et al. Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor α (infliximab) versus placebo in active spondyloarthropathy. Arthritis Rheum 2002;46:755-65.
32. Van den Bosch F, Kruithof E, Baeten D et al. Safety and efficacy of a retreatment regimen of 10mg/kg infliximab every 14 weeks in patients with active spondyloarthropathy. Arthritis Rheum 2002;46 (9 Suppl.):S430.
33. Kruithof E, Van den Bosch F, Baeten D, De Keyser F, Mielants H, Veys EM. Repeated infusions of infliximab, a chimeric anti TNF α monoclonal antibody, in patients with active spondyloarthropathy: one year follow up. Ann Rheum Dis 2002;61:207-12.
34. Breban M, Vignon E, Claudpierre P et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six month open-label study. Rheumatology 2002;41:1280-5.
35. Hadi A, Hickling P, Brown M, Al-Nahas A. Scintigraphic evidence of effect of infliximab on disease activity in ankylosing spondylitis. Rheumatology 2002;41:114-6.
36. Maksymowych W, Jhangri G, Lambert R et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002;29: 959-65.
37. Braun J, Baraliakos X, Golder W et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. Arthritis Rheum 2003;48:1126-36.
38. Cooper C, Carbone L, Michet CJ, Atkinson EJ, O'Fallon WM, Melton LJ 3rd. Fracture risk inpatients with ankylosing spondylitis: a population based study. J Rheumatol 1994;21:1877-82.
39. Bessant R, Keat J. Audit of the diagnosis, assessment, and treatment of osteoporosis in patients with ankylosing spondylitis. J Rheumatol 2003;30:779-82.
40. Mitra D, Elvins DM, Speden DJ, Collins AJ. The prevalence of vertebral fractures in mild ankylosing spondylitis and their relationship to bone mineral density. Rheumatology 2000;39:85-9.
41. Allai F, Breban M, Porcher R, Maillefert JF, Dougados M, Roux C. Increase in bone mineral density of patients with spondyloarthropathy treated with anti-tumor necrosis factor alpha. Ann Rheum Dis 2003;62:347-9.
42. Baeten D, Kruithof E, Van den Bosch F et al. Immunmodulatory effects of anti-tumor necrosis factor therapy on synovium in spondyloarthropathy. Arthritis Rheum 2001;44:186-95.
43. Brandt J, Haibel H, Sieper J, Reddig J, Braun J. Treatment of severe ankylosing spondylitis: one-year follow up. Arthritis Rheum 2001; 44:2936-45.
44. Summary of Product Characteristics. Remicade. Leiden, The Netherlands: Centocor. May 2003.
45. Summary of Product Characteristics. Enbrel. Maidenhead, UK; Wyeth. January 2004.
46. Gorman J, Sack K, Davis J. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor α. N Engl J Med 2002;346: 1349-56.
47. Davis JC Jr, Van Der Heijde D, Braun J et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis. A randomised controlled trial. Arthritis Rheum 2003;48: 3230-6.
48. Brandt J, Khariouzov A, Listing J et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003; 48:1667-75.
49. Mease P, Goffe BS, Metz J, VanderStop A, Finck B, Burge D. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised controlled trial. Lancet 2000;356:385-90.
50. Antoni A, Ogilvie A, Lueftl M et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). Arthritis Rheum 2002;46(Suppl. 9):S381.
51. Brandt J, Haibel H, Reddig J, Sieper J, Braun J. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-α monoclonal antibody infliximab. J Rheumatol 2002;29:118-22.
52. Oili KS, Niinisalo H, Korpilahde T, Virolainen J. Treatment of reactive arthritis with infliximab. Scand J Rheumatol 2003;32: 122-4.
53. Marzo-Ortega H, McGonagle D, O'Connor P, Emery P. Efficacy of etanercept for treatment of Crohn's related spondyloarthritis but not colitis. Ann Rheum Dis 2003;62:74-6.
54. Van den Bosch F, Kruithoff E, De Vos M, Der Keyser F, Mielants H. Crohn's disease associated with spondyloarthropathy: effect of TNF-α blockade with infliximab on articular symptoms. Lancet 2000;356:1821-2.
55. El-Shabrawi Y, Hermann J. Anti-tumor necrosis factor-alpha therapy with infliximab as an alternative to corticosteroids in the treatment of human leukocyte antigen B27 associated acute anterior uveitis. Ophthalmology 2002;109:2342-6.
56. Pham T, Van der Heijde D, Calin A et al. for the ASAS working group. Initiation of biological agents in patients with ankylosing spondylitis: results of a Delphi study by the ASAS Group. 1 Ann Rheum Dis 2003;62:812-6.
57. Masymowych W, Inman R, Gladman D, Thompson G, Stone M, Karsh J, Russell A; Spondyloarthritis Research Consortium of Canada (SPARCC). Canadian Rheumatology Association consensus on the use of anti-tumor necrosis factor-alpha directed therapies in the treatment of spondyloarthritis. J Rheumatol 2003;30: 1356-63.
58. Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF 36). Conceptual framework and item selection. Med Care 1992;30:473-83.
59. Helliwell PS, Doward L, Whalley D et al. Psychometric and scaling properties of a new quality of life instrument specific to ankylosing spondylitis. Arthritis Rheum 1999;42(Suppl. 9):S72.